Drug delivery devices with drug-permeable component and methods

Patent metadata

Field	Value
Publication number	US-10315019-B2
Application number	US-201414216112-A
Country	US
Kind code	B2
Filing date	Mar 17, 2014
Priority date	Mar 15, 2013
Publication date	Jun 11, 2019
Grant date	Jun 11, 2019

Abstract

Implantable drug delivery devices include a housing having a closed drug reservoir lumen bounded by a first wall structure and a hydrophilic second wall structure, and a drug contained in the drug reservoir lumen, wherein the first wall structure is impermeable to the drug and the second wall structure is permeable to the drug. Methods of providing controlled release of drug to a patient include deploying a drug delivery device in the patient releasing a drug from the drug reservoir lumen via diffusion through the second wall structure.

First claim

We claim:

1. An intravesical drug delivery device comprising:
a housing having a closed drug reservoir lumen bounded by a first wall structure and a hydrophilic second wall structure, wherein the drug reservoir lumen is closed such that no aperture extends through the housing; and
one or more solid drug units comprising a high weight fraction of a drug, the one or more solid drug units being contained in the drug reservoir lumen,
wherein the first wall structure is impermeable to the drug, and the second wall structure is formed of a material that is permeable to the drug,
wherein the first wall structure is an elongated cylindrical tube and the second wall structure is an end wall in the form of a disk stabilized in a lumen of the elongated cylindrical tube, and
wherein the first and second wall structures are water permeable, such that the device is configured to release solubilized drug from the closed drug reservoir lumen by diffusion through only the material forming the second wall structure upon the one or more solid drug units being contacted by water that enters the drug reservoir lumen through the first and second wall structures.

2. The device of claim 1 , wherein the device is configured for intravesical insertion and retention.

3. The device of claim 2 , wherein the device is elastically deformable between a relatively straightened shape suited for insertion through a urethra of a patient and into a bladder of the patient and a retention shape suited to retain the device within the bladder.

4. The device of claim 3 , further comprising a retention frame lumen and a retention frame disposed therein.

5. The device of claim 1 , wherein the first wall structure comprises silicone.

6. The device of claim 1 , wherein the second wall structure comprises a thermoplastic polyurethane.

7. The device of claim 1 , wherein the disk is sandwiched between an inner washer and an outer washer.

8. The device of claim 1 , wherein the drug is a low solubility drug.

9. The device of claim 1 , wherein the drug is a high solubility drug.

10. The device of claim 1 , wherein the drug comprises lidocaine, gemcitabine, docetaxel, carboplatin, cisplatin, oxaliplatin, trospium, tolterodine, oxybutynin, or mitomycin C.

11. The device of claim 1 , wherein the device is configured to be free floating in a patient's bladder upon deployment.

12. The device of claim 1 , wherein:
the first wall structure comprises silicone having a Shore hardness of from 50A to 70A, and
the second wall structure comprises a thermoplastic polyurethane having a Shore hardness of from 70A to 65D.

13. An intravesical drug delivery device, comprising:
a housing having a closed drug reservoir lumen bounded by a first wall structure and a hydrophilic second wall structure, such that no aperture extends through the housing, wherein the first wall structure is an elongated cylindrical tube and the second wall structure is an end wall disposed at one end or both ends of the cylindrical tube, and wherein the first and second wall structures are water permeable; and
a drug in solid form contained in the drug reservoir lumen,
wherein the second wall structure comprises a thermoplastic polyurethane,
wherein the device is configured, upon deployment in a bladder of a patient, to permit water to diffuse into the closed drug reservoir lumen and solubilize the drug and then to permit the solubilized drug to diffuse through the thermoplastic polyurethane forming the second wall structure but not through the first wall structure, which is impermeable to the drug, and
wherein the device is elastically deformable between a relatively straightened shape suited for insertion through a urethra of the patient and into the bladder and a retention shape suited to retain the device within the bladder.

14. The device of claim 13 , further comprising a retention frame lumen and a retention frame disposed therein.

15. The device of claim 13 , wherein the first wall structure comprises silicone.

16. The device of claim 15 , wherein the silicone has a Shore hardness of from 50A to 70A.

17. The device of claim 16 , wherein the second wall structure comprises a thermoplastic polyurethane having a Shore hardness of from 70A to 65D.

18. The device of claim 13 , wherein the second wall structure is in the form of a disk stabilized in a lumen of the elongated cylindrical tube.

19. The device of claim 18 , wherein the disk is sandwiched between an inner washer and an outer washer.

Assignees

• Taris Biomedical Llc

Inventors

• Lee Heejin
• Daniel Karen
• Sansone Matthew

Classifications

• A61K31/337

  having four-membered rings, e.g. taxol · CPC title

• A61K9/0034

  Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants · CPC title

• A61K9/0024

  Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L) · CPC title

• A61K31/167

  having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol · CPC title

• A61K31/407

  condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine · CPC title